<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wendy Tsang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roberto M Lang, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Candice Silversides, MD, MS, FRCPC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peripartum cardiomyopathy (PPCM, also called pregnancy-associated cardiomyopathy) is a rare cause of heart failure (HF) that affects women late in pregnancy or in the early puerperium [<a href="#rid1">1</a>]. Although initially described in 1849 [<a href="#rid2">2</a>], it was not recognized as a distinct clinical entity until the 1930s [<a href="#rid3">3</a>]. </p><p>This topic will discuss the etiology, clinical manifestations, and diagnosis of PPCM. Treatment and prognosis of PPCM, critical illness during pregnancy and the peripartum period, HF during pregnancy, and issues related to pregnancy in women with acquired or congenital heart disease are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95071.html" rel="external">"Peripartum cardiomyopathy: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1629.html" rel="external">"Critical illness during pregnancy and the peripartum period"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3507.html" rel="external">"Management of heart failure during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>A variety of definitions have been used to identify PPCM [<a href="#rid1">1,4-7</a>]. The definition developed by the 2010 European Society of Cardiology (ESC) Working Group on Peripartum Cardiology is the most widely used and has been included in the 2018 ESC guidelines on management of cardiovascular diseases during pregnancy and in the position statement from the Heart Failure Association of the European Society of Cardiology Study Group on PPCM [<a href="#rid1">1,7,8</a>]. The definition is broad, as the Working Group sought to avoid underdiagnosis of PPCM, and all three conditions must be met [<a href="#rid8">8</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Development of HF in the last month of pregnancy (or toward the end of pregnancy) or within five months following delivery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of another identifiable cause for the HF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular (LV) systolic dysfunction with an LV ejection fraction (LVEF) of less than 45 percent, with or without LV dilation.</p><p></p><p>The last criterion was added to prevent the inclusion of patients with disorders with higher LVEF that mimic systolic HF [<a href="#rid6">6,9</a>]. Such disorders include accelerated hypertension, diastolic dysfunction, systemic infection, pulmonary embolism, or complications of late pregnancy (eg, preeclampsia or amniotic fluid embolus). </p><p>Some patients with higher LVEF (between 45 and 50 percent) may be diagnosed with PPCM if they have typical clinical features; in such patients, the diagnosis should be made after all other causes have been excluded [<a href="#rid8">8</a>]. Prior definitions also exclude cardiomyopathy that presented as HF before the last month of pregnancy [<a href="#rid4">4-6</a>], although the disease process is likely the same.</p><p class="bulletIndent1"><span class="glyph">●</span>One study of 123 females suggested that PPCM and earlier forms of pregnancy cardiomyopathy are likely the same disease [<a href="#rid10">10</a>]. One hundred women met the traditional criteria for PPCM, presenting at a mean of 38 weeks, and 23 presented earlier at a mean of 32 weeks. There were no differences between the two groups in terms of age, race, associated conditions, LVEF (29 versus 27 percent), the rate and time of recovery, and maternal outcomes.</p><p></p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H467788223"><span class="h2">Global differences in incidence</span><span class="headingEndMark"> — </span>A large prospective international registry of 411 women from 43 countries has demonstrated that PPCM occurs globally, affecting women from all ethnicities on all continents [<a href="#rid11">11</a>]. However, incidence rates vary widely depending on geographical location. Published incidences of PPCM range widely  (<a class="graphic graphic_figure graphicRef127868" href="/d/graphic/127868.html" rel="external">figure 1</a>) [<a href="#rid1">1,5,9,12-23</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>1:100 in Zaria, Nigeria </p><p class="bulletIndent1"><span class="glyph">●</span>1:300 in Haiti</p><p class="bulletIndent1"><span class="glyph">●</span>1:1000 in South Africa</p><p class="bulletIndent1"><span class="glyph">●</span>1:1000 to 1:4000 in the United States</p><p class="bulletIndent1"><span class="glyph">●</span>1:2400 in Canada</p><p class="bulletIndent1"><span class="glyph">●</span>1: 5719 in Sweden</p><p class="bulletIndent1"><span class="glyph">●</span>1:10,149 in Denmark</p><p class="bulletIndent1"><span class="glyph">●</span>1:20,000 live births in Japan</p><p></p><p>The incidence data for many other countries such as those in the Middle East, Asia, South America, and Australia are not well described. Also, the true incidence of PPCM may be higher, as milder forms may be missed. </p><p>The wide range in reported incidence may reflect an overestimation in studies that rely solely on clinical criteria to make the diagnosis (see <a class="local">'Diagnosis'</a> below). There may also be differences in search criteria and a lack of chart review when large national registries are used. Also, socioeconomic disparities between countries may contribute to some of these observed differences.</p><p>A genetic predisposition may contribute to geographical variability. The higher prevalence in Haiti supports the notion that females in the African diaspora have a higher risk of developing PPCM. Nonracial regional variations in PPCM also exist, as demonstrated in a large study that reported differences in women from the Kanto region compared with other areas in Nigeria [<a href="#rid24">24,25</a>]. </p><p>The incidence of PPCM is also increasing [<a href="#rid19">19</a>]. This may be due to improved diagnosis and recognition but also increasing maternal age, preeclampsia, multiparity, multiple gestations, and maternal cardiovascular risk factors.</p><p class="headingAnchor" id="H1088888575"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The mean age at PPCM presentation is 31 years, and the mean parity is 3 [<a href="#rid11">11</a>].</p><p>The following are factors associated with increased risk of PPCM:</p><p class="bulletIndent1"><span class="glyph">●</span>Age greater than 30 years [<a href="#rid3">3,4,10,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>African descent [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy with multiple gestation [<a href="#rid10">10,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior or concurrent preeclampsia, eclampsia, or postpartum hypertension [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal cocaine abuse [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term (&gt;4 weeks) oral tocolytic therapy with beta adrenergic agonists such as <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parity ≥4 [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Although multiparity is associated with PPCM [<a href="#rid31">31</a>], studies have shown that the majority of patients who develop PPCM do so during the first or second pregnancy [<a href="#rid10">10,32,33</a>]. </p><p></p><p>Some of the above risk factors (preeclampsia, hypertensive disorders in pregnancy, and cocaine cardiomyopathy) are themselves etiologies of HF in late pregnancy. Early studies of patients with PPCM have often excluded women with preeclampsia to avoid misclassification of patients. However, high incidences of preeclampsia are seen in patients with PPCM, suggesting that preeclampsia is associated with predisposition to PPCM through a shared pathophysiologic mechanism [<a href="#rid11">11,28,34,35</a>].</p><p>Diabetes has been reported as a risk factor for PPCM, but this relationship may be confounded by other risk factors such as hypertensive disorders during pregnancy, which is a more established risk factor for PPCM and is also often associated with diabetes [<a href="#rid22">22</a>].</p><p>There are conflicting data as to whether <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> deficiency is [<a href="#rid36">36,37</a>] or is not [<a href="#rid38">38</a>] a risk factor for PPCM [<a href="#rid10">10,31-33</a>].</p><p class="headingAnchor" id="H472416772"><span class="h2">Race-ethnic differences</span><span class="headingEndMark"> — </span>While there are differences in incidence and severity among ethnic groups, a prospective worldwide registry found that mode of presentation and mean age were similar across ethnic, socioeconomic, and geographic backgrounds [<a href="#rid11">11</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong> – In the United States, African Americans have a higher prevalence of PPCM compared with White Americans and may also have more severe disease. In a series comparing 52 African Americans and 104 White Americans with PPCM, African American patients were younger, had a higher prevalence of gestational hypertension, and lower rates of recovery of ventricular function, which resulted in a higher rate of the combined endpoint of mortality and cardiac transplantation [<a href="#rid39">39,40</a>]. However, socioeconomic disparities may contribute to this observed difference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Canada</strong> – A retrospective study found that Aboriginal Canadian women with PPCM presented with lower LVEFs and larger LVs than other Canadian women with PPCM [<a href="#rid11">11,41</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENIC FACTORS</span><span class="headingEndMark"> — </span>Whereas no single unifying cause for PPCM has been identified, several contributing pathogenic factors have been identified. Experimental research suggests that in the setting of pregnancy-related maternal cardiovascular changes, these multiple factors result in a common final pathway with enhanced oxidative stress, cleavage of prolactin to an angiostatic N-terminal 16 kDA prolactin fragment, and impaired vascular endothelial growth factor (VEGF) signaling because of upregulated soluble fms-like tyrosine kinase [<a href="#rid1">1,9,34,42</a>].</p><p class="headingAnchor" id="H580877314"><span class="h2">Angiogenic imbalance</span><span class="headingEndMark"> — </span>Data from studies in mice and humans suggest that PPCM may be caused by systemic angiogenic imbalance via a lack of PGC-1α, a key regulator of pro-angiogenic VEGF. [<a href="#rid28">28,34,43,44</a>]. Hypertensive disorders in pregnancy may also contribute to the development of PPCM via angiogenic imbalance, particularly if preeclampsia is present. </p><p class="headingAnchor" id="H3706496280"><span class="h2">Role of prolactin</span><span class="headingEndMark"> — </span>Altered prolactin processing is believed to be involved in the pathogenesis of PPCM. The 16 kDa prolactin cleavage fragment (16K PRL) causes endothelial damage and myocardial dysfunction, possibly by inducing endothelial cell microRNA-146a expression [<a href="#rid42">42</a>]. Women with PPCM have elevated levels of microRNA-146a compared with healthy postpartum women or women with other cardiomyopathies [<a href="#rid42">42</a>]. </p><p>Studies in mice suggest that PPCM can result from reduction in the transcription factor STAT3, which also increases one form of 16K PRL [<a href="#rid45">45</a>]. Reduced STAT3 may not be specific to PPCM, as it is seen in both dilated cardiomyopathy (DCM) and PPCM [<a href="#rid46">46</a>].</p><p>The potential role of prolactin as a target in the treatment of PPCM is discussed separately. (See  <a class="medical medical_review" href="/d/html/95071.html" rel="external">"Peripartum cardiomyopathy: Treatment and prognosis", section on 'Bromocriptine or antiprolactin therapy'</a>.)</p><p class="headingAnchor" id="H752559493"><span class="h2">Pregnancy-related hemodynamic changes</span><span class="headingEndMark"> — </span>Normal pregnancy is considered a hemodynamic cardiovascular "stress test" such that an uncomplicated pregnancy is analogous to completing a normal stress test. </p><p class="bulletIndent1"><span class="glyph">●</span>The most marked hemodynamic stress occurs toward the end of pregnancy, during delivery, and early postpartum. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal cardiovascular physiologic changes include increased LV volumes, LV mass, and circulating blood volume; dilutional anemia; and shunting of up to 25 percent of circulating blood to the fetus and placenta. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It has been hypothesized that women with specific genetic and/or other biologic susceptibilities may develop PPCM at the end of pregnancy or early postpartum, when there is more marked cardiovascular stress. </p><p></p><p class="headingAnchor" id="H3322527433"><span class="h2">Other biologic factors</span></p><p class="headingAnchor" id="H922145808"><span class="h3">Genetic predisposition</span><span class="headingEndMark"> — </span>Evidence from several studies supports the hypothesis that PPCM may develop as the combined result of pregnancy-related factors and a susceptible genetic background. The following observations support a genetic underpinning of PPCM: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>PPCM and DCM clustering </strong>– PPCM and DCM have been noted to cluster in families, and DCM-associated mutations have been identified in some patients with PPCM [<a href="#rid47">47-49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic variants </strong>– Variants in eight genes were shared in individuals with PPCM and DCM, suggesting shared genetics between these two conditions. The identified genetic variants were more common in PPCM and DCM than in a control population with no cardiomyopathy [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Two-thirds of identified truncating variants were in a gene (gene name TTN) that encodes the sarcomere protein titin that is known to be associated with DCM. The presence of a TTN-truncating variant was significantly correlated with lower LVEF at one-year follow-up. Thus, some patients with PPCM and these TTN-truncating variants may be presenting with an initial manifestation of familial DCM. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history and worse LV recovery </strong>– Studies have reported that women with a family history of DCM have poorer recovery rates than those without a family history [<a href="#rid47">47,49</a>]. </p><p></p><p class="headingAnchor" id="H3231336564"><span class="h4">Interplay between genetics and race-ethnicity</span><span class="headingEndMark"> — </span>A specific genetic variant linked to hypertension is more common in Black females and may underlie lower LVEF recovery among Black females with PPCM. The guanine nucleotide-binding protein beta-3 subunit (GNB3) has a polymorphism called C825T [<a href="#rid51">51</a>] that is associated with an increased risk of hypertension, low plasma renin, and cardiac remodeling [<a href="#rid51">51</a>]. It has a prevalence of 50 percent in Black individuals compared with 10 percent in White individuals. In a study of 97 women, the GNB3 TT genotype was associated with lower LVEF at 6 and 12 months in women with PPCM. </p><p class="headingAnchor" id="H2757616593"><span class="h3">Immunologic factors</span></p><p class="headingAnchor" id="H6"><span class="h4">Inflammatory cytokines</span><span class="headingEndMark"> — </span>Inflammatory cytokines may play a role in the pathogenesis and progression of cardiomyopathy and HF. The cytokines that are elevated in PPCM compared with controls include tumor necrosis factor alpha and interleukin-6 [<a href="#rid52">52,53</a>]. In addition, Fas/Apo-1, an apoptosis signaling receptor, and C-reactive protein are associated with more severe disease [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/3506.html" rel="external">"Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Other factors'</a>.)</p><p class="headingAnchor" id="H3718840413"><span class="h4">Maternal immune response to fetal microchimerism</span><span class="headingEndMark"> — </span>The available data are both mixed and insufficient to establish whether abnormal maternal immunological response is the cause of PPCM. It has been suggested that a maternal immunologic response to a fetal antigen (also called fetal microchimerism) can lead to PPCM. Fetal cells may escape into the maternal circulation and remain there without being rejected due to weak immunogenicity of the paternal haplotype of the chimeric cells [<a href="#rid54">54</a>]. If these cells lodge in the cardiac tissue, they can trigger a pathologic autoimmune response [<a href="#rid5">5</a>].</p><p>There are high titers of autoantibodies (to cardiac myosin, adenine nucleotide translocator, and branched chain alpha ketoacid dehydrogenase) in PPCM compared with controls [<a href="#rid5">5,55</a>]. However, in a study of humoral immunity in 39 Nigerian women with PPCM, there was no difference in the levels of serum immunoglobulins, circulating immune complexes, or cardiac muscle antibodies between subjects and controls [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1684464487"><span class="h2">Infectious and environmental factors</span></p><p class="headingAnchor" id="H7"><span class="h3">Myocarditis</span><span class="headingEndMark"> — </span>Though some investigators have suggested myocarditis as a possible cause of PPCM [<a href="#rid57">57-61</a>], the role of myocarditis in PPCM is uncertain [<a href="#rid62">62</a>]. </p><p>Observations from small case series suggest a possible role for myocarditis: </p><p class="bulletIndent1"><span class="glyph">●</span>One study showed healing myocarditis in endomyocardial biopsies in 5 of 11 patients with PPCM. Absence of myocarditis on biopsy was associated with improvement in HF and LV remodeling [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two other series of 14 and 18 patients, respectively, myocarditis was present in 29 and 78 percent of patients with PPCM, respectively [<a href="#rid59">59,60</a>]. In comparison, myocarditis was present in 9 percent of 55 patients with non-pregnancy-related idiopathic cardiomyopathy [<a href="#rid59">59</a>]. Among 26 patients with PPCM who had evidence of interstitial inflammation, viral genomes were noted in eight (31 percent) [<a href="#rid61">61</a>]. Viral genomes have also been noted in other forms of myocarditis. (See  <a class="medical medical_review" href="/d/html/4933.html" rel="external">"Myocarditis: Causes and pathogenesis", section on 'Viral or "idiopathic" myocarditis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a nonrandomized study, three patients with PPCM and myocarditis were treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and showed clinical improvement with no inflammatory infiltrate on repeat biopsy [<a href="#rid57">57</a>].</p><p></p><p>One study not supportive of myocarditis as a PPCM etiology: </p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of endomyocardial biopsy specimens from 34 patients fulfilling the clinical criteria for a diagnosis of PPCM found a lower incidence of myocarditis (9 percent) than that reported in other studies [<a href="#rid62">62</a>]. This incidence was comparable to that found in an age- and sex-matched control population undergoing transplantation for idiopathic DCM (9.1 percent).</p><p></p><p>Study limitations that limit our ability to conclude whether myocarditis is a PPCM pathogenic factor include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion of patients outside the accepted time frame of PPCM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variability among patient populations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limitations of endomyocardial biopsy as a means of diagnosis of myocarditis. </p><p></p><p class="bulletIndent1">The timing of biopsy in relation to the onset of symptoms may also be important, since the incidence of inflammation is greater in patients who are biopsied soon after presentation [<a href="#rid60">60,62</a>]. Other limitations include sampling error (since myocardial involvement may be patchy) and variability in histologic criteria for myocarditis (ie, whether patients with borderline myocarditis were included together with those with active myocarditis as defined by the Dallas criteria) [<a href="#rid5">5</a>]. </p><p></p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H947516721"><span class="h2">Timing of presentation</span><span class="headingEndMark"> — </span>PPCM is less commonly seen before 36 weeks of gestation, and affected patients usually present during the first month postpartum [<a href="#rid10">10,63,64</a>]. Most women with PPCM are diagnosed early after delivery during readmission after discharge [<a href="#rid8">8</a>]. No significant differences in demographics, presentation, or hospital outcomes are noted between those who present during pregnancy or after delivery.</p><p>Pregnant women with other types of cardiac disease (eg, ischemic, valvular, or myopathic) may present earlier in the antepartum period, coincident with increases in the hemodynamic burden imposed by the gravid state during the second trimester, though they may also present during the third trimester or postpartum [<a href="#rid65">65</a>]. Thus, although late presentation during pregnancy can be helpful to identify women with PPCM, the entire clinical picture should be considered. (See  <a class="medical medical_review" href="/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a> and  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p class="headingAnchor" id="H1395435592"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Presentation of PPCM is variable and similar to other forms of systolic HF due to cardiomyopathy [<a href="#rid1">1</a>]. Patients most commonly complain of dyspnea; other typical symptoms include cough, orthopnea, paroxysmal nocturnal dyspnea, pedal edema, and hemoptysis. Initial diagnosis may be delayed since symptoms such as nonspecific fatigue, shortness of breath, and pedal edema are similar to those that occur in normal pregnancy but more pronounced [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p>Physical signs can include an elevated jugular venous pressure, a displaced apical impulse, a third heart sound, and a murmur of mitral regurgitation [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Physical examination'</a>.)</p><p>Signs and symptoms of systemic or pulmonary thromboembolism may be present. Case series have reported varying rates of thromboembolism [<a href="#rid9">9,67-69</a>], and further data are needed to quantify the risk of this complication [<a href="#rid1">1</a>]. Patients with PPCM and LVEF &lt;35 percent are at risk for developing LV thrombus. As an example, LV thrombus was identified by echocardiography in 16 of 100 patients with PPCM (with mean LVEF of 26 percent) in one series [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p class="headingAnchor" id="H947517023"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H123050170"><span class="h2">Criteria for diagnosis</span><span class="headingEndMark"> — </span>As noted above, the diagnosis of PPCM is based upon three clinical criteria [<a href="#rid4">4-6</a>]: development of HF toward the end of pregnancy or in the months following delivery, absence of another identifiable cause of HF, and LV systolic dysfunction with an LVEF generally &lt;45 percent [<a href="#rid1">1</a>]. (See <a class="local">'Definition'</a> above.)</p><p>Diagnostic investigations should be directed to timely diagnosis and treatment.</p><p class="headingAnchor" id="H2296091974"><span class="h2">Diagnostic testing</span><span class="headingEndMark"> — </span>An electrocardiogram (ECG) and echocardiogram should be performed in patients who are suspected of having PPCM. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p class="headingAnchor" id="H3582306636"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>An ECG should be performed in all patients with suspected PPCM to detect other conditions in the differential diagnosis such as myocardial infarction and pulmonary embolism. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>ECG abnormalities may be found in up to 50 percent of patients with PPCM, but a normal ECG does not exclude PPCM [<a href="#rid70">70</a>]. ECG findings in patients with PPCM are nonspecific and include sinus tachycardia (or rarely atrial fibrillation) and nonspecific ST- and T-wave abnormalities. Anterior precordial Q waves and prolonged PR intervals and QRS duration are occasionally present [<a href="#rid4">4,13</a>]. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Electrocardiogram'</a>.)</p><p class="headingAnchor" id="H1426765520"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>An echocardiogram should be performed in all patients in whom the diagnosis of PPCM is being considered. The echocardiogram generally reveals a global reduction in LV systolic function with LVEF nearly always &lt;45 percent [<a href="#rid1">1</a>]. The LV is frequently but not always dilated  (<a class="graphic graphic_diagnosticimage graphicRef60087" href="/d/graphic/60087.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef96206" href="/d/graphic/96206.html" rel="external">image 2</a>) [<a href="#rid1">1</a>]. Doppler assessment of right ventricular systolic pressures can usually also be performed, making right heart catheterization unnecessary in most patients. </p><p>Other possible echocardiographic findings include left atrial enlargement, LV or left atrial thrombus  (<a class="graphic graphic_diagnosticimage graphicRef60087" href="/d/graphic/60087.html" rel="external">image 1</a>), dilated right ventricle, right ventricular hypokinesis, mitral and tricuspid regurgitation, and rarely small pericardial effusion [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Echocardiography'</a>.)</p><p class="headingAnchor" id="H3850508642"><span class="h3">Chest radiograph</span><span class="headingEndMark"> — </span>A chest radiograph is not necessary to make a diagnosis of HF or PPCM, and it exposes the patient to ionizing radiation  (<a class="graphic graphic_table graphicRef50090" href="/d/graphic/50090.html" rel="external">table 1</a>). If, despite a thorough physical examination, the diagnosis of pulmonary edema is uncertain, and a chest radiograph is deemed necessary to make that diagnosis, it can be considered and discussed with the pregnant patient, and fetal-shielding should be used. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p>Chest radiograph typically shows enlargement of the cardiac silhouette with evidence of pulmonary venous congestion and/or interstitial edema, and, on occasion, pleural effusions. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Chest radiograph'</a>.)</p><p class="headingAnchor" id="H781762323"><span class="h3">Plasma brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP)</span><span class="headingEndMark"> — </span>measurement is suggested in the evaluation of patients with suspected HF, especially when the diagnosis is uncertain. Women presenting with PPCM typically have elevated BNP and NT-proBNP levels that are higher than those seen in healthy women during pregnancy or postpartum [<a href="#rid72">72</a>]. Measurement of BNP levels during pregnancy is discussed further separately. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Brain natriuretic peptide'</a> and  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p class="headingAnchor" id="H2186927416"><span class="h3">Other less frequently used tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral and bacterial cultures, as well as viral titers</strong> (eg, Coxsackie B) are generally not indicated. The results of these tests are nonspecific and thus without proven value in patients with myocarditis. (See  <a class="medical medical_review" href="/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Identifying the cause of myocarditis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plasma concentrations of proangiogenic and antiangiogenic factors</strong> including placenta growth factor, fms-like-tyrosine-kinase 1 receptor, and their ratios have been proposed to be used to distinguish patients with PPCM. These studies are still very preliminary [<a href="#rid34">34,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac magnetic resonance</strong> <strong>imaging (CMR)</strong> – CMR is not generally required to make the diagnosis of PPCM, but it can be helpful to assess LV systolic function and LV volumes, particularly if echocardiography is technically suboptimal. Experience with CMR in PPCM is limited, and its role is still being evaluated [<a href="#rid73">73-80</a>]. The safety of these techniques in pregnancy and the importance of risk versus benefit in decision-making are discussed separately. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Use of gadolinium'</a>.)</p><p></p><p class="bulletIndent1">Case reports and small series have noted variable presence of late gadolinium enhancement (LGE) in patients with PPCM [<a href="#rid75">75-80</a>]. The presence and persistence of LGE may be associated with poor recovery of cardiac function [<a href="#rid79">79</a>]; improving LGE may be associated with cardiac recovery [<a href="#rid76">76</a>], while lack of LGE may be associated with presence or absence of cardiac recovery [<a href="#rid78">78</a>]. However, a later study could not confirm these findings [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Late gadolinium enhancement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac catheterization </strong>– Invasive cardiac tests are usually not used to diagnose PPCM [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Right heart catheterization</strong> – This is rarely needed because assessment of cardiac pressures can usually be made with physical examination and Doppler echocardiography. It may be helpful in critically ill patients who need more complete assessment or ongoing evaluation of their hemodynamic state.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Left heart catheterization and angiography </strong>– Unlike new onset HF in the non-pregnant person, investigation for coronary artery disease as the primary cause of the cardiomyopathy is usually not necessary. Left heart catheterization with coronary angiography is only indicated in selected patients in whom coronary artery disease is highly suspected. (See  <a class="medical medical_review" href="/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization", section on 'Signs of ongoing myocardial dysfunction or infarction'</a>.)</p><p></p><p class="bulletIndent2">Diagnostic coronary angiography exposes the patient to ionizing radiation (equivalent to approximately 100 or more chest radiographs)  (<a class="graphic graphic_table graphicRef50090" href="/d/graphic/50090.html" rel="external">table 1</a>), and therefore it is important to carefully consider the appropriate timing of testing, to discuss the risks of fluoroscopy with the patient, and to employ fetal shielding if the procedure must be performed during pregnancy. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endomyocardial biopsy </strong>– Similar to new onset HF in the non-pregnant patient, endomyocardial biopsy is generally not required in patients with suspected PPCM. There are no pathognomonic findings in PPCM. As noted above, a variable proportion of patients have evidence of myocarditis. Other histologic findings in PPCM can include myocardial hypertrophy and/or degeneration, fibrosis, and interstitial edema [<a href="#rid4">4,12</a>]. </p><p></p><p class="bulletIndent2">The decision as to whether or not to perform an endomyocardial biopsy should be left to the discretion of the physician and patient. The &lt;1 percent risk of serious complications may not be reasonable given low clinical benefit from the findings.</p><p></p><p class="bulletIndent2">Recommendations for endomyocardial biopsy in general are discussed separately. (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p></p><p class="headingAnchor" id="H2086949959"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>We often consider genetic counseling and testing in those with a positive family history of dilated cardiomyopathy, sudden death, or PPCM. This is because approximately 10 to 20 percent of women with HF in the peripartum period carry mutations known to induce cardiomyopathies [<a href="#rid35">35,47-50,83</a>]. Some of these inherited dilated cardiomyopathies develop during early adulthood and may be difficult to differentiate from PPCM. Alternatively, patients with these genetic abnormalities may have a predisposition to developing HF that is triggered by the physiological stress of pregnancy and delivery. People with a genetic predisposition to PPCM may also have a genetic predisposition to other diseases such as cancer [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/4911.html" rel="external">"Genetics of dilated cardiomyopathy"</a>.) </p><p class="headingAnchor" id="H84779113"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>PPCM is a diagnosis of exclusion. Some pre-existing cardiac lesions may manifest during pregnancy due to pregnancy-associated hemodynamic changes (see  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Physiology of normal pregnancy'</a>). As noted in the 2010 European Society of Cardiology (ESC) working group statement on PPCM, the following conditions should be considered in the differential diagnosis [<a href="#rid1">1,85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-existing cardiomyopathy </strong>– Any cardiomyopathy may be unmasked during pregnancy including idiopathic dilated cardiomyopathy (DCM), familial DCM, or HIV/AIDS cardiomyopathy (which often presents without ventricular dilatation). In patients with a pre-existing cardiomyopathy, HF is more likely to manifest antepartum or early in pregnancy. In contrast, PPCM most commonly presents postpartum. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Cardiomyopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-existing valvular disease</strong> – Either acquired or valvular disease can be unmasked by pregnancy. These conditions often present in the antenatal period in contrast to PPCM, which generally presents in late pregnancy or postpartum. Valvular heart disease is diagnosed by physical examination and echocardiography. (See  <a class="medical medical_review" href="/d/html/97124.html" rel="external">"Pregnancy and valve disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitral stenosis, most commonly from rheumatic heart disease, is more commonly seen in women from endemic regions. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aortic stenosis (usually from bicuspid or other congenital disease), aortic regurgitation (often from a bicuspid aortic valve), and mitral regurgitation are other valve lesions that cause HF during pregnancy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PPCM can also lead to functional valvular disease from chamber dilation, annular dilation, and leaflet tethering, which can impair leaflet coaptation. Mitral regurgitation can result from these changes in PPCM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-existing undetected congenital heart disease</strong> – Aside from bicuspid valve disease, the most common congenital lesions that may be first diagnosed during pregnancy are atrial septal defects, ventricular septal defects, and patent ductus arteriosus. The clinical presentation and echocardiography are helpful in diagnosing these lesions. (See  <a class="medical medical_review" href="/d/html/1415.html" rel="external">"Pregnancy in women with congenital heart disease: Specific lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diastolic HF due to hypertensive heart disease </strong>– This diagnosis is suggested by a prior history of severe hypertension and consistent findings on echocardiography. (See  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial infarction </strong>– Although myocardial infarction is rare in women of childbearing age, some studies have suggested an increased risk during pregnancy and during the early postpartum period. Causes of myocardial infarction during pregnancy include coronary artery dissection, coronary artery disease, coronary embolus/thrombosis (in a normal coronary artery), and coronary artery spasm. Risk factors include older maternal age, hypertension, diabetes mellitus, and obesity. Clinical manifestations include anginal chest pain, ECG changes, elevations in cardiac biomarkers, and regional wall motion abnormalities on echocardiography. (See  <a class="medical medical_review" href="/d/html/89.html" rel="external">"Acute myocardial infarction and pregnancy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary embolus </strong>– Pregnancy and the early postpartum period are associated with increased risk of venous thrombosis and pulmonary embolism, but diagnosis of pulmonary embolus can be challenging. The presence of dyspnea without evidence of HF favors the diagnosis of pulmonary embolus over PPCM. Pulmonary embolus can be diagnosed by lung scintigraphy or computed tomographic pulmonary angiography, as discussed separately. (See  <a class="medical medical_review" href="/d/html/89374.html" rel="external">"Pulmonary embolism in pregnancy: Clinical presentation and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H1724330643"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118887.html" rel="external">"Society guideline links: Management of cardiovascular diseases during pregnancy"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>–<strong> </strong>Peripartum cardiomyopathy (PPCM) is defined as the development of systolic heart failure (HF) toward the end of pregnancy or in the months following pregnancy, with left ventricular ejection fraction (LVEF) generally less than 45 percent in the absence of another identifiable cause of HF. (See <a class="local">'Definition'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The prevalence of PPCM is highly country and region specific, ranging from 1 in 100 in Haiti, 1 in 1000 to 4000 in the United States, and 1 in 20,000 in Japan. Risk factors for PPCM include greater age, parity, multiple gestation, African descent, and a history of preeclampsia, eclampsia, or postpartum hypertension. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenic factors </strong>– The etiology of PPCM is unknown, but the final common pathway includes angiogenic imbalance and altered prolactin processing. Possible causes include genetic, inflammatory, hormonal, hemodynamic, infectious, and autoimmune factors. (See <a class="local">'Pathogenic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The clinical presentation of PPCM is variable and similar to new onset systolic HF due to cardiomyopathy in the non-pregnant person. Onset during late pregnancy and early postpartum are unique to PPCM. Common findings include dyspnea, lower extremity edema, increased jugular venous pressure, and crackles on lung exam. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic test findings </strong>– An electrocardiogram (ECG), echocardiogram, and brain natriuretic peptide (BNP) are performed in most patients. A chest radiograph showing pulmonary edema exposes the patient and fetus to ionizing radiation and is rarely necessary to confirm a diagnosis of PPCM. Other tests are less useful.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ECG </strong>– This is usually nonspecific in PPCM showing sinus tachycardia but can help distinguish from other conditions such as acute myocardial infarction or right heart strain from a pulmonary embolus. (See <a class="local">'Electrocardiogram'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Echocardiogram </strong>– This shows global reduction in LV systolic function, with LVEF nearly always &lt;45 percent. The LV is frequently but not always dilated. (See <a class="local">'Echocardiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis –</strong> PPCM is a diagnosis of exclusion. Other causes of HF should be considered including other types of pre-existing cardiomyopathy, valvular heart disease, congenital heart disease, hypertension-related diastolic HF, myocardial infarction, and pulmonary embolism.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767.</a></li><li><a class="nounderline abstract_t">Richie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb Med Surg J 1849; 2:333.</a></li><li><a class="nounderline abstract_t">Hafkesbring E, Hull E. "Toxic" postpartal heart disease. New Orleans Med Surg J 1937; 89:550.</a></li><li><a class="nounderline abstract_t">Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44:1053.</a></li><li><a class="nounderline abstract_t">Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283:1183.</a></li><li><a class="nounderline abstract_t">Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94:311.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiol Pol 2019; 77:245.</a></li><li><a class="nounderline abstract_t">Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21:827.</a></li><li><a class="nounderline abstract_t">Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995; 130:860.</a></li><li><a class="nounderline abstract_t">Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111:2050.</a></li><li><a class="nounderline abstract_t">Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 2017; 19:1131.</a></li><li><a class="nounderline abstract_t">SEFTEL H, SUSSER M. Maternity and myocardial failure in African women. Br Heart J 1961; 23:43.</a></li><li><a class="nounderline abstract_t">Davidson NM, Parry EH. The etiology of peripartum cardiac failure. Am Heart J 1979; 97:535.</a></li><li><a class="nounderline abstract_t">WOOLFORD RM. Postpartum myocardosis. Ohio State Med J 1952; 48:924.</a></li><li><a class="nounderline abstract_t">PIERCE JA, PRICE BO, JOYCE JW. Familial occurrence of postpartal heart failure. Arch Intern Med 1963; 111:651.</a></li><li><a class="nounderline abstract_t">Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.</a></li><li><a class="nounderline abstract_t">Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80:1602.</a></li><li><a class="nounderline abstract_t">Sliwa K, Böhm M. Incidence and prevalence of pregnancy-related heart disease. Cardiovasc Res 2014; 101:554.</a></li><li><a class="nounderline abstract_t">Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 2014; 3:e001056.</a></li><li><a class="nounderline abstract_t">Barasa A, Rosengren A, Sandström TZ, et al. Heart Failure in Late Pregnancy and Postpartum: Incidence and Long-Term Mortality in Sweden From 1997 to 2010. J Card Fail 2017; 23:370.</a></li><li><a class="nounderline abstract_t">Ersbøll AS, Johansen M, Damm P, et al. Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. Eur J Heart Fail 2017; 19:1712.</a></li><li><a class="nounderline abstract_t">Dhesi S, Savu A, Ezekowitz JA, Kaul P. Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women. Can J Cardiol 2017; 33:911.</a></li><li><a class="nounderline abstract_t">Isogai T, Kamiya CA. Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality. Int Heart J 2019; 60:503.</a></li><li><a class="nounderline abstract_t">Karaye KM, Sa'idu H, Balarabe SA, et al. Clinical Features and Outcomes of Peripartum Cardiomyopathy in Nigeria. J Am Coll Cardiol 2020; 76:2352.</a></li><li><a class="nounderline abstract_t">Karaye KM, Ishaq NA, Sai'du H, et al. Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria. ESC Heart Fail 2021; 8:3257.</a></li><li><a class="nounderline abstract_t">Veille JC. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol 1984; 148:805.</a></li><li><a class="nounderline abstract_t">Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312:1432.</a></li><li><a class="nounderline abstract_t">Bello N, Rendon IS, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 2013; 62:1715.</a></li><li><a class="nounderline abstract_t">Mendelson MA, Chandler J. Postpartum cardiomyopathy associated with maternal cocaine abuse. Am J Cardiol 1992; 70:1092.</a></li><li><a class="nounderline abstract_t">Lampert MB, Hibbard J, Weinert L, et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993; 168:493.</a></li><li><a class="nounderline abstract_t">Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 2011; 118:583.</a></li><li><a class="nounderline abstract_t">Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152:509.</a></li><li><a class="nounderline abstract_t">Chapa JB, Heiberger HB, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005; 105:1303.</a></li><li><a class="nounderline abstract_t">Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485:333.</a></li><li><a class="nounderline abstract_t">Goli R, Li J, Brandimarto J, et al. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation 2021; 143:1852.</a></li><li><a class="nounderline abstract_t">Kothari SS. Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction? Int J Cardiol 1997; 60:111.</a></li><li><a class="nounderline abstract_t">Cénac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol 1992; 36:57.</a></li><li><a class="nounderline abstract_t">Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol 2002; 86:311.</a></li><li><a class="nounderline abstract_t">Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail 2013; 19:214.</a></li><li><a class="nounderline abstract_t">Irizarry OC, Levine LD, Lewey J, et al. Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non-African American Women. JAMA Cardiol 2017; 2:1256.</a></li><li><a class="nounderline abstract_t">Liu S, Zuberi SA, Malik AA, et al. Peripartum Cardiomyopathy Characteristics and Outcomes in Canadian Aboriginal and Non-Aboriginal Women. Can J Cardiol 2017; 33:471.</a></li><li><a class="nounderline abstract_t">Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123:2143.</a></li><li><a class="nounderline abstract_t">Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376:631.</a></li><li><a class="nounderline abstract_t">Sliwa K, Mebazaa A. Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome. Eur Heart J 2014; 35:680.</a></li><li><a class="nounderline abstract_t">Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128:589.</a></li><li><a class="nounderline abstract_t">Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003; 107:798.</a></li><li><a class="nounderline abstract_t">van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169.</a></li><li><a class="nounderline abstract_t">Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010; 121:2176.</a></li><li><a class="nounderline abstract_t">van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 2014; 35:2165.</a></li><li><a class="nounderline abstract_t">Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med 2016; 374:233.</a></li><li><a class="nounderline abstract_t">Sheppard R, Hsich E, Damp J, et al. GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study. Circ Heart Fail 2016; 9:e002683.</a></li><li><a class="nounderline abstract_t">Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000; 35:701.</a></li><li><a class="nounderline abstract_t">Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27:441.</a></li><li><a class="nounderline abstract_t">Nelson JL. Pregnancy, persistent microchimerism, and autoimmune disease. J Am Med Womens Assoc (1972) 1998; 53:31.</a></li><li><a class="nounderline abstract_t">Ansari AA, Fett JD, Carraway RE, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002; 23:301.</a></li><li><a class="nounderline abstract_t">Cénac A, Beaufils H, Soumana I, et al. Absence of humoral autoimmunity in peripartum cardiomyopathy. A comparative study in Niger. Int J Cardiol 1990; 26:49.</a></li><li><a class="nounderline abstract_t">Melvin KR, Richardson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982; 307:731.</a></li><li><a class="nounderline abstract_t">Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 1986; 56:285.</a></li><li><a class="nounderline abstract_t">O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 1986; 8:52.</a></li><li><a class="nounderline abstract_t">Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81:922.</a></li><li><a class="nounderline abstract_t">Bültmann BD, Klingel K, Näbauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193:363.</a></li><li><a class="nounderline abstract_t">Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994; 74:474.</a></li><li><a class="nounderline abstract_t">Sanderson JE, Adesanya CO, Anjorin FI, Parry EH. Postpartum cardiac failure--heart failure due to volume overload? Am Heart J 1979; 97:613.</a></li><li><a class="nounderline abstract_t">Lee W. Clinical management of gravid women with peripartum cardiomyopathy. Obstet Gynecol Clin North Am 1991; 18:257.</a></li><li><a class="nounderline abstract_t">Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009; 55:45.</a></li><li><a class="nounderline abstract_t">Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25:118.</a></li><li><a class="nounderline abstract_t">Kane A, Mbaye M, Ndiaye MB, et al. [Evolution and thromboembolic complications of the idiopathic peripartal cardiomyopathy at Dakar University Hospital: forward-looking study about 33 cases]. J Gynecol Obstet Biol Reprod (Paris) 2010; 39:484.</a></li><li><a class="nounderline abstract_t">Simeon IA. Echocardiographic profile of peripartum cardiomyopathy in a tertiary care hospital in sokoto, Nigeria. Indian Heart J 2006; 58:234.</a></li><li><a class="nounderline abstract_t">Mandal D, Mandal S, Mukherjee D, et al. Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy. J Obstet Gynaecol Res 2011; 37:222.</a></li><li><a class="nounderline abstract_t">Honigberg MC, Elkayam U, Rajagopalan N, et al. Electrocardiographic findings in peripartum cardiomyopathy. Clin Cardiol 2019; 42:524.</a></li><li><a class="nounderline abstract_t">Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart 2011; 97:1970.</a></li><li><a class="nounderline abstract_t">Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10:861.</a></li><li><a class="nounderline abstract_t">Fett JD. The role of MRI in peripartum cardiomyopathy. Int J Cardiol 2009; 137:185.</a></li><li><a class="nounderline abstract_t">Baruteau AE, Leurent G, Martins RP, et al. Peripartum cardiomyopathy in the era of cardiac magnetic resonance imaging: first results and perspectives. Int J Cardiol 2010; 144:143.</a></li><li><a class="nounderline abstract_t">Leurent G, Baruteau AE, Larralde A, et al. Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis. Int J Cardiol 2009; 132:e91.</a></li><li><a class="nounderline abstract_t">Kawano H, Tsuneto A, Koide Y, et al. Magnetic resonance imaging in a patient with peripartum cardiomyopathy. Intern Med 2008; 47:97.</a></li><li><a class="nounderline abstract_t">Caballero-Borrego J, García-Pinilla JM, Rueda-Calle E, de Teresa-Galván E. [Evidence of gadolinium late-enhancement on cardiac magnetic resonance imaging in a patient with peripartum cardiomyopathy]. Rev Esp Cardiol 2008; 61:219.</a></li><li><a class="nounderline abstract_t">Mouquet F, Lions C, de Groote P, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 2008; 18:2765.</a></li><li><a class="nounderline abstract_t">Marmursztejn J, Vignaux O, Goffinet F, et al. Delayed-enhanced cardiac magnetic resonance imaging features in peripartum cardiomyopathy. Int J Cardiol 2009; 137:e63.</a></li><li><a class="nounderline abstract_t">Barone-Rochette G, Rodière M, Lantuejoul S. Value of cardiac MRI in peripartum cardiomyopathy. Arch Cardiovasc Dis 2011; 104:263.</a></li><li><a class="nounderline abstract_t">Schelbert EB, Elkayam U, Cooper LT, et al. Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Isogai T, Matsui H, Tanaka H, et al. In-hospital management and outcomes in patients with peripartum cardiomyopathy: a descriptive study using a national inpatient database in Japan. Heart Vessels 2017; 32:944.</a></li><li><a class="nounderline abstract_t">van Spaendonck-Zwarts KY, van Rijsingen IA, van den Berg MP, et al. Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. Eur J Heart Fail 2013; 15:628.</a></li><li><a class="nounderline abstract_t">Pfeffer TJ, Schlothauer S, Pietzsch S, et al. Increased Cancer Prevalence in Peripartum Cardiomyopathy. JACC CardioOncol 2019; 1:196.</a></li><li><a class="nounderline abstract_t">Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016; 18:1096.</a></li></ol></div><div id="topicVersionRevision">Topic 4945 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675664" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : "Toxic" postpartal heart disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4256828" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural course of peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703781" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432149" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30912108" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31243866" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572598" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851613" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271625" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13749643" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Maternity and myocardial failure in African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/425884" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The etiology of peripartum cardiac failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13003102" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Postpartum myocardosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13943404" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Familial occurrence of postpartal heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330699" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Epidemiology and etiology of cardiomyopathy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16342653" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24459193" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence and prevalence of pregnancy-related heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24901108" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069474" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Heart Failure in Late Pregnancy and Postpartum: Incidence and Long-Term Mortality in Sweden From 1997 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597481" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31019181" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33183509" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical Features and Outcomes of Peripartum Cardiomyopathy in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34137499" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6367478" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Peripartum cardiomyopathies: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3887170" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013055" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414911" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postpartum cardiomyopathy associated with maternal cocaine abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8438916" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Peripartum heart failure associated with prolonged tocolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860287" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923422" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Improved outcomes in peripartum cardiomyopathy with contemporary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15932821" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic value of echocardiography in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22596155" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33874732" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209949" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1428253" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419571" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582086" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049825" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non-African American Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169090" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Peripartum Cardiomyopathy Characteristics and Outcomes in Canadian Aboriginal and Non-Aboriginal Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619365" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598363" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24302271" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289576" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591746" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458010" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458009" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24558114" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735901" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915373" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716473" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143707" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458623" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pregnancy, persistent microchimerism, and autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12402414" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autoimmune mechanisms as the basis for human peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298518" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Absence of humoral autoimmunity in peripartum cardiomyopathy. A comparative study in Niger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110225" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Peripartum cardiomyopathy due to myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756045" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Peripartum heart disease: an endomyocardial biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711532" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306840" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Peripartum myocarditis and cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098856" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High prevalence of viral genomes and inflammation in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059728" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Incidence of myocarditis in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/433737" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Postpartum cardiac failure--heart failure due to volume overload?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945254" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical management of gravid women with peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117363" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pregnancy outcomes in women with dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660481" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472372" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [Evolution and thromboembolic complications of the idiopathic peripartal cardiomyopathy at Dakar University Hospital: forward-looking study about 33 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033622" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Echocardiographic profile of peripartum cardiomyopathy in a tertiary care hospital in sokoto, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114580" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843220" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Electrocardiographic findings in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22058286" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnosis and management of peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768352" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684520" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The role of MRI in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171402" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Peripartum cardiomyopathy in the era of cardiac magnetic resonance imaging: first results and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258317" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195498" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Magnetic resonance imaging in a patient with peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18364197" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : [Evidence of gadolinium late-enhancement on cardiac magnetic resonance imaging in a patient with peripartum cardiomyopathy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18642002" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439378" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Delayed-enhanced cardiac magnetic resonance imaging features in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21624795" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Value of cardiac MRI in peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28373243" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233090" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : In-hospital management and outcomes in patients with peripartum cardiomyopathy: a descriptive study using a national inpatient database in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349452" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396183" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Increased Cancer Prevalence in Peripartum Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338866" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
